FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
28/08/2023
Voltar para busca
Dado oficial do USPTO
ONMYNT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
28/08/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
10/02/2022
Data de registro
25/04/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/04/2023
Última transação
25/04/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
CH
Examinador
DUBIN, DAVID
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparationspharmaceutical preparations for use in dermatology; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Classe 10
Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; Medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for the diagnosis and treatment of gastro-intestinal diseases; medical apparatus and instruments for the diagnosisprevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; medical apparatus and instruments for use in hematology and in tissue and organ transplantation; medical apparatus and instruments for the diagnosisprevention and treatment of eye diseases and conditions; medical apparatus and instruments for the diagnosisprevention and treatment of heart rhythm disorders; medical apparatus and instruments for the diagnosisprevention and treatment of immune system related diseases and disorders; medical apparatus and instruments for the diagnosisprevention and treatment of kidney diseases; medical apparatus and instruments for the diagnosisprevention and treatment of diabetes; medical apparatus and instruments for the diagnosisprevention and treatment of hypertension; medical apparatus and instruments for the diagnosisprevention and treatment of skin disorders; medical apparatus and instruments for use in urology; medical apparatus and instruments for ophthalmological use; medical apparatus and instruments for the diagnosisprevention and treatment of cancer and tumors; medical apparatus and instruments for the diagnosisprevention and treatment of allergies; medical apparatus and instruments for the diagnosisprevention and treatment of bone diseases; medical apparatus and instruments for the diagnosisprevention and treatment of respiratory diseases and asthma; radiological apparatus and instruments for medical use in the nature of radiological apparatus for medical purposes; genetic testing apparatus and instruments for medical use in the nature of genetic testing apparatus for medical purposes; electromagnetic drug delivery apparatus and instruments for medical use in the nature of electromagnetic drug delivery apparatus for medical use; medical apparatus and instruments for diagnostic radiopharmaceutical use; medical apparatus and instruments for facilitating the inhalation of pharmaceutical preparations in the nature of medical apparatus for facilitating the inhalation of pharmaceutical preparations; apparatus and instruments for DNA and RNA testing for medical use in the nature of apparatus for DNA and RNA testing for medical purposes; medical apparatusinfusion and injection devices for administering drugs; medical apparatus and instruments for introducing pharmaceutical preparations into the human body in the nature of medical apparatus for introducing pharmaceutical preparations into the human body
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/08/2023
FIMP
FINAL DISPOSITION PROCESSED
04/08/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/07/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
25/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
25/04/2023
GPNX
NOTIFICATION PROCESSED BY IB
07/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/02/2023
PUBO
PUBLISHED FOR OPPOSITION
07/02/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/01/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/11/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/11/2022
RFNP
REFUSAL PROCESSED BY IB
27/09/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/09/2022
RFRR
REFUSAL PROCESSED BY MPU
01/09/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/08/2022
CNRT
NON-FINAL ACTION WRITTEN
02/08/2022
DOCK
ASSIGNED TO EXAMINER
02/08/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
20/06/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
20/06/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
20/06/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
20/06/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
20/06/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
20/06/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
06/06/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
26/05/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ONMYNT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.